SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
 Rebranding and Consolidating BioMarin’s Comprehensive Support and Services for Eligible Rare Disease Patients - EconoTimes)
SAN RAFAEL, Calif., Feb. 29, 2016 -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the launch of BioMarin RareConnectionsTM, rebranding its patient-focused offering formally known as the BioMarin Patient and Physician Support (BPPS). For over 10 years, BioMarin has been a leader in designing and implementing multiple separate service offerings to support our patients. With the launch of BioMarin RareConnections, it now provides them under one expanded program, which includes clinical support for eligible patients throughout treatment and assistance to gain and maintain access to BioMarin’s innovative therapies.
BioMarin RareConnections offers personalized assistance to patients in the United States, who have been prescribed or are considering a BioMarin therapy for Morquio A, MPS VI and phenylketonuria (PKU), and their caregivers. While specific services will vary by medication, BioMarin RareConnections support includes access to dedicated case managers and clinical coordinators, as well as help securing insurance coverage and/or financial assistance. Additional services may include coordination of medication deliveries and disease and product education.
“Patients and their families battling rare conditions face uncommon challenges. As a leader in the community, it is our responsibility to provide unparalleled support to help ensure our patients, who are eligible for BioMarin approved therapies, have access to, and are connected with, the exceptional care they deserve,” said Jeff Ajer, Chief Commercial Officer of BioMarin. “We are proud that BioMarin RareConnections will house all of our support services in one area to help us serve as a trusted partner in care.”
To learn more about BioMarin RareConnections, call 1-866-906-6100 or email [email protected].
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com.
Contact: Investors: Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media: Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451
